Bridger Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bridger Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-56,053	Closed	-$35M	–	39
2020 Q2	$35M	Sell	56,053 -35,744	-39%	-$20.3M	3.24%	16
2020 Q1	$44.8M	Buy	+91,797	New	+$37.9M	5.19%	5
2017 Q3	–	Sell	-51,505	Closed	-$25.3M	–	38
2017 Q2	$25.3M	Buy	+51,505	New	+$22.5M	1.44%	29
2015 Q3	–	Sell	-54,132	Closed	-$27.6M	–	45
2015 Q2	$27.6M	Buy	+54,132	New	+$26.4M	0.87%	32
2014 Q4	–	Sell	-16,218	Closed	-$5.85M	–	45
2014 Q3	$5.85M	Buy	+16,218	New	+$5.44M	0.4%	39
2014 Q2	–	Sell	-55,000	Closed	-$16.5M	–	45
2014 Q1	$16.5M	Buy	+55,000	New	+$16.9M	1.1%	34

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridger Management's REGN Position: Q3 2020 in Review

Bridger Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 56,053 shares — an estimated $35M sold.

Bridger Management first reported a position in REGN in Q1 2014 and held it in 6 quarters. The position peaked at $44.8M in Q1 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

Bridger Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bridger Management sold 56,053 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $35M.
Bridger Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Bridger Management's Regeneron Pharmaceuticals position peaked at $44.8M in Q1 2020.
907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Bridger Management's 13F filing for Q3 2020, filed 16 Nov 2020.